Screening in GI cancers: The role of genetics

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1721-1728

  Stoffel, Elena M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER PREVENTION; CANCER SCREENING; COLORECTAL CANCER; COWDEN SYNDROME; DIGESTIVE SYSTEM CANCER; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GENETIC PREDISPOSITION; GENETIC RISK; GENOMICS; GERMLINE MUTATION; HAMARTOMATOUS POLYPOSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT IDENTIFICATION; PHENOTYPE; POLYPOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH ADENOCARCINOMA; STOMACH CANCER; ANIMAL; EARLY DIAGNOSIS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC SCREENING; GENETICS; HEREDITY; PATHOLOGY; PEDIGREE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR;

TUMOR MARKER;

ANIMALS; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITY; HUMANS; INDIVIDUALIZED MEDICINE; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84937150562     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.6764     Document Type: Review

References (59)

1. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 339:1546-1558, 2013
2. Fearon ER, Carethers JM: Molecular subtyping of colorectal cancer: Time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 148:10-13, 2015
3. Lu KH, Wood ME, Daniels M, et al: American Society of Clinical Oncology expert statement: Collection and use of a cancer family history for oncology providers. J Clin Oncol 32:833-840, 2014
4. Hampel H, Frankel WL, Martin E, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783-5788, 2008
5. Jasperson KW, Tuohy TM, Neklason DW, et al: Hereditary and familial colon cancer. Gastroenterology 138:2044-2058, 2010
6. Siegel RL, Jemal A, Ward EM: Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 18:1695-1698, 2009
7. Levin B, Lieberman DA, McFarland B, et al: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134:1570-1595, 2008
8. Fuchs CS, Giovannucci EL, Colditz GA, et al: A prospective study of family history and the risk of colorectal cancer. N Engl J Med 331:1669-1674, 1994
9. Vasen HF, Mecklin JP, Khan PM, et al: The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34:424-425, 1991
10. Hampel H, Frankel WL, Martin E, et al: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851-1860, 2005
11. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004
12. Chen S, Wang W, Lee S, et al: Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296:1479-1487, 2006
13. Kastrinos F, Steyerberg EW, Mercado R, et al: The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140:73-81, 2011
14. Grover S, Stoffel EM, Bussone L, et al: Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2:813-819, 2004
15. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361:2449-2460, 2009
16. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
17. Pritchard CC, Grady WM: Colorectal cancer molecular biology moves into clinical practice. Gut 60:116-129, 2011
18. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
19. Palles C, Cazier JB, Howarth KM, et al: Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45:136-144, 2013
20. Quehenberger F, Vasen HF, van Houwelingen HC: Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: Correction for ascertainment. J Med Genet 42:491-496, 2005
21. Jenkins MA, Baglietto L, Dowty JG, et al: Cancer risks for mismatch repair gene mutation carriers: A population-based early onset case-family study. Clin Gastroenterol Hepatol 4:489-498, 2006
22. Stoffel E, Mukherjee B, Raymond VM, et al: Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621-1627, 2009
23. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214-218, 1999
24. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35-41, 2009
25. Palomaki GE, McClain MR, Melillo S, et al: EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11:42-65, 2009
26. Giardiello FM, Allen JI, Axilbund JE, et al: Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 147:502-526, 2014
27. Win AK, Parry S, Parry B, et al: Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 20:1829-1836, 2013
28. Järvinen HJ, Aarnio M, Mustonen H, et al: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834, 2000
29. Mecklin JP, Aarnio M, Läärä E, et al: Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 133:1093-1098, 2007
30. Vasen HF, Abdirahman M, Brohet R, et al: One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300-2306, 2010
31. Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-269, 2006
32. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
33. Grover S, Kastrinos F, Steyerberg EW, et al: Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 308:485-492, 2012
34. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Genetic/familial high risk assessment: Colorectal (version 2.2014). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
35. Stoffel EM, Mangu PB, Gruber SB, et al: Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer-European Society for Medical Oncology clinical practice guidelines. J Clin Oncol 33:209-217, 2015
36. Balaguer F, Castellví-Bel S, Castells A, et al: Identification of MYH mutation carriers in colorectal cancer: A multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 5:379-387, 2007
37. Giardiello FM, Trimbath JD: Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 4:408-415, 2006
38. van Lier MG, Wagner A, Mathus-Vliegen EM, et al: High cancer risk in Peutz-Jeghers syndrome: A systematic review and surveillance recommendations. Am J Gastroenterol 105:1258-1264, 2010; author reply 65
39. Mester J, Eng C: Cowden syndrome: Recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol 111:125-130, 2015
40. Heald B, Mester J, Rybicki L, et al: Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 139:1927-1933, 2010
41. Lindor NM, Rabe K, Petersen GM, et al: Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: Familial colorectal cancer type X. JAMA 293:1979-1985, 2005
42. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014
43. Chun N, Ford JM: Genetic testing by cancer site: Stomach. Cancer J 18:355-363, 2012
44. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
45. Masciari S, Dewanwala A, Stoffel EM, et al: Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 13:651-657, 2011
46. Fitzgerald RC, Hardwick R, Huntsman D, et al: Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436-444, 2010
47. Lim YC, di Pietro M, O'Donovan M, et al: Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointest Endosc 80:78-87, 2014
48. Biankin AV, Waddell N, Kassahn KS, et al: Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399-405, 2012
49. Zhen DB, Rabe KG, Gallinger S, et al: BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: A PACGENE study. Genet Med [epub ahead of print on November 20, 2014]
50. Grant RC, Selander I, Connor AA, et al: Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148:556-564, 2015
51. Kastrinos F, Mukherjee B, Tayob N, et al: Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790-1795, 2009
52. Wolpin BM, Rizzato C, Kraft P, et al: Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet 46:994-1000, 2014
53. Comen EA, Robson M: Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park) 24:55-62, 2010
54. Canto MI, Harinck F, Hruban RH, et al: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62:339-347, 2013
55. Kurian AW, Hare EE, Mills MA, et al: Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001-2009, 2014
56. Walsh T, Casadei S, Lee MK, et al: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108:18032-18037, 2011
57. Domchek SM, Bradbury A, Garber JE, et al: Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net? J Clin Oncol 31:1267-1270, 2013
58. Robson ME, Storm CD, Weitzel J, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893-901, 2010
59. Manolio TA, Collins FS, Cox NJ, et al: Finding the missing heritability of complex diseases. Nature 461:747-753, 2009